share_log

Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target

Benzinga ·  Aug 7 13:59  · Ratings

Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment